EVFM - Evofem Biosciences GAAP EPS of $0.10 revenue of $5.11M
2023-11-14 06:58:57 ET
More on Evofem Biosciences
- Evofem Biosciences expects to see third consecutive quarter of growth
- Evofem says no Phexxi generic until 2033 after company amends ANDA
- Financial information for Evofem Biosciences
For further details see:
Evofem Biosciences GAAP EPS of $0.10, revenue of $5.11M